FIELD: medicine.
SUBSTANCE: invention refers to medicinal agents for use in medicine. Described pharmaceutical composition for treating non-alcoholic fatty liver disease, characterized by that it is obtained from the following medicinal raw materials: from 26.25 g to 180 g of silybin, 45 g to 195 g of soya phospholipid, 75 g to 450 g of Pu'er tea extract.
EFFECT: technical result is that the drug exhibits efficacy in treating non-alcoholic fatty liver disease.
12 cl, 23 ex, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND RADIX PUERARIAE EXTRACT | 2016 |
|
RU2697670C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND L-CARNITINE | 2016 |
|
RU2699011C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND VITAMIN E | 2016 |
|
RU2695806C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN, VITAMIN E AND L-CARNITINE | 2016 |
|
RU2700793C2 |
| PHARMACEUTICAL COMBINATION CONTAINING SILYBIN | 2016 |
|
RU2695224C2 |
| USE OF PEGYLATED RECOMBINANT CHIMERIC MOUSE FIBROBLAST-21 GROWTH FACTOR OR ITS PHARMACEUTICALLY ACCEPTABLE SALT IN COMPOSITION OF DRUGS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | 2018 |
|
RU2785582C2 |
| COMPOSITION AND METHOD OF PREVENTION, REMOVAL OF SYMPTOMS OR THERAPEUTIC EFFECT ON LIVER DAMAGE | 2020 |
|
RU2810601C2 |
| MEANS FOR NON-ALCOHOLIC FATTY LIVER DISEASE TREATMENT AND PREVENTION | 2016 |
|
RU2644282C2 |
| PHARMACEUTICAL COMBINATION, COMPOSITION, AND COMBINED COMPOSITION, CONTAINING GLUCOKINASE ACTIVATOR AND PPAR RECEPTOR ACTIVATOR, AND THEIR PREPARATION METHOD, AND THEIR USE | 2019 |
|
RU2781638C2 |
| COMPOSITION FOR PREVENTING OR TREATING FATTY LIVER DISEASES | 2015 |
|
RU2664696C2 |
